

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

2694-1

U.S. APPLICATION NO. (If known)

09/24/97

INTERNATIONAL APPLICATION NO.

PCT/EP97/04353

INTERNATIONAL FILING DATE

August 11, 1997

PRIORITY DATE CLAIM

August 12

TITLE OF INVENTION

NEW ANTIVIRAL LIPOPETIDES, AND A METHOD OF INACTIVATING LIPID-ENVELOPED VIRUS
LIPOPETIDES

APPLICANT(S) FOR DO/EO/US


VOLLENBROICH, Dirk; VATER, Joachim; PAULI, Georg; KAMP, Roza Maria

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 33.
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claim date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(3)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(2)).
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98. , 1449- and International Search Report
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:
 - 1.) Zero (0) sheets of Formal Drawings

U.S. APPLICATION NO (if known, see 37 CFR 1.5)		INTERNATIONAL APPLICATION NO		ATTORNEY'S DOCKET NUMBER	
NEW		PCT/EP97/04353		2694-11	
17. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS	
BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. \$970.00					
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$930.00					
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO. \$760.00					
International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$670.00					
International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4). \$96.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =					
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$ 930.00	
				\$ 130.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	12 - 20 =	0	X \$18.00	\$ 0	
Independent Claims	2 - 3 =	0	X \$78.00	\$ 0	
MULTIPLE DEPENDENT CLAIM(S) (if applicable) No			+ \$260.00	\$ 0	
TOTAL OF ABOVE CALCULATIONS =				\$ 1060.00	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				\$	
SUBTOTAL =				\$ 1060.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$ 1060.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$	
TOTAL FEES ENCLOSED =				\$ 1060.00	
				Amount to be:	
				refunded \$	
				charged \$	
a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>1060.00</u> to cover the above fees is enclosed.					
b. <input type="checkbox"/> Please charge my Deposit Account. No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.					
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>02-2448</u> .					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
Send all correspondence to: Birch, Stewart, Kolasch & Birch, LLP P.O. Box 747 Falls Church, VA 22040-0747 (703)205-8000					
 SIGNATURE					
<u>MUNCY, JOE MCKINNEY</u> NAME					
<u>32,334</u> REGISTRATION NUMBER					
/dlg February 12, 1999					

**STATEMENT CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) & 1.27(b))--INDEPENDENT INVENTOR**

Docket Number (Option
2694-119P

Applicant, Patentee, or Identifier: VOLLENBROICH, Dirk et al

Application or Patent No.: New

Filed or Issued: February 12, 1999

Title: NEW ANTIVIRAL LIPOPETIDES, AND A METHOD OF INACTIVATING
LIPID-ENVELOPED VIRUSES USING LIPOPETIDES

As a below named inventor, I hereby state that I qualify as an independent inventor as defined in 37 CFR 1.9(c) for purposes of paying reduced fees to the Patent and Trademark Office described in:

- ☐ the specification filed herewith with title as listed above.
☒ the application identified above.
☐ the patent identified above.

I have not assigned, granted, conveyed, or licensed, and am under no obligation under contract or law to assign, grant, convey, or license, any rights in the invention to any person who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern, or organization to which I have assigned, granted, conveyed, or licensed or am under obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below.

- ☒ No such person, concern, or organization exists.
☐ Each such person, concern, or organization is listed below.

Separate statements are required from each named person, concern, or organization having rights to the invention stating their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28)

Roza Maria KAMP

NAME OF INVENTOR

NAME OF INVENTOR

NAME OF INVENTOR

Roza Maria KAMP
Signature of inventor

Signature of inventor

Signature of inventor

16.03.1999
Date

Date

Date

**STATEMENT CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) & 1.27(b))--INDEPENDENT INVENTOR**

Docket Number (Option
2694-119P

Applicant, Patentee, or Identifier: VOLLENBROICH, Dirk et al

Application or Patent No.: New

Filed or Issued: February 12, 1999

Title: NEW ANTIVIRAL LIPOPETIDES, AND A METHOD OF INACTIVATING
LIPID-ENVELOPED VIRUSES USING LIPOPETIDES

As a below named inventor, I hereby state that I qualify as an independent inventor as defined in 37 CFR 1.9 for purposes of paying reduced fees to the Patent and Trademark Office described in:

- ☐ the specification filed herewith with title as listed above.
☒ the application identified above.
☐ the patent identified above.

I have not assigned, granted, conveyed, or licensed, and am under no obligation under contract or law to assign, grant, convey, or license, any rights in the invention to any person who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).


Each person, concern, or organization to which I have assigned, granted, conveyed, or licensed or am under obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below.

- ☒ No such person, concern, or organization exists.
☐ Each such person, concern, or organization is listed below.

Separate statements are required from each named person, concern, or organization having rights to the invention stating their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28)

Dirk VOLLENBROICH
NAME OF INVENTOR


Signature of inventor

18.03.1999
Date

Joachim VATER
NAME OF INVENTOR


Signature of inventor

16/3 / 1999
Date

Georg PAULI
NAME OF INVENTOR


Signature of inventor

18.03.99
Date

IN THE U.S. PATENT AND TRADEMARK OFFICE

APPLICANTS: VOLLENBROICH, Dirk et al

INTL. APPLN. NO.: PCT/EP97/04353

SERIAL NO.: NEW

GROUP:

FILED: February 12, 1999

EXAMINER:

FOR: NEW ANTIVIRAL LIPOPETIDES, AND A METHOD OF INACTIVATING
LIPID-ENVELOPED VIRUSES USING LIPOPETIDES

PRELIMINARY AMENDMENT

BOX PATENT APPLICATION

Assistant Commissioner of Patents
and Trademarks
Washington, D.C. 20231

February 12, 1999

Sir:

The following Preliminary Amendments and Remarks are respectfully submitted
in connection with the above-identified application.

IN THE SPECIFICATION:

Before line 1, insert --This application is the national phase under 35 U.S.C. §371
of prior PCT International Application No. PCT/EP97/04353 which has an International
filing date of August 11, 1997 which designated the United States of America.--

IN THE CLAIMS:

CLAIM 3: Line 1, delete "or 2"

CLAIM 4: Line 1, change "any of claims 1-3" to --claim 1--

CLAIM 6: Line 1, delete "or 5"

CLAIM 7: Line 1, change "any of Claims 4-6" to --Claim 4--

CLAIM 8: Line 1, change "any of Claims 4-6" to --Claim 4--

CLAIM 9: Line 1, change "any of Claims 1-8" to --Claim 1--

CLAIM 10: Line 1, change "any of Claims 1-8" to --Claim 1--

REMARKS

The specification has been amended to provide a cross-reference to the previously filed International Application.

The above amendment to the claims is merely to delete undesired multiple dependencies and places the application into better form prior to examination.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. §1.16 or under 37 C.F.R. §1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By Joe McKinney Muncy
JOE MCKINNEY/MUNCY
Reg. No. 32,334
P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

KM/dlg

**New Antiviral Lipopeptides, and a Method of Inactivating
Lipid-enveloped Viruses Using Lipopeptides**

The invention relates to an extraordinarily efficient method of inactivating lipid-enveloped viruses such as herpes or retroviruses in biological or biotechnological - particularly pharmaceutical - products, as well as in cell cultures by adding a cyclic lipopeptide or a mixture of lipopeptides or salts or esters thereof at specific concentrations. Lipopeptides were found to have a surprisingly high inactivation potential for lipid-enveloped viruses and in addition, they offer the advantage of an exceedingly low *in vivo* toxicity, so that the step of removing the inactivating agent from pharmaceutical products or cell culture can be omitted. The invention is also directed to new antiviral lipopeptides which belong to the surfactins.

At the latest, the AIDS epidemic has brought the realization into the mind of the general public that not only HI viruses but rather, a variety of agents pathogenic for humans may be transmitted, for example, via blood transfusions, pharmaceuticals, transplantations, etc.. In general, it is obligatory today that each pharmaceutical agent prepared from biological material or having come in contact with same is rated as potentially contaminated with microbes or viruses, and that infection-related safety must be verified. As a result of the development of molecular-biological methods for manufacturing pharmaceutical agents, the risk of infection by various microbial contaminants has increased further. Animal or human cell lines are frequently used in the biotechnological production of pharm

ceuticals. In these cells, in particular, virus infections by endogenous viruses, latent virus infections, or contaminations cannot be excluded completely. The infection-related safety of biotechnological pharmaceuticals, e.g., vaccines, monoclonal antibodies, hormones, or recombinant proteins therefore necessitates removal of any infectious, undesirable particles, which, in principle, may be associated with a considerable loss of research time and means or productivity. Virus safety of blood and blood products can only be guaranteed by testing and selecting the blood donations, in combination with evaluating and prophylactically using efficient and reliable methods of virus inactivation and elimination.

To inactivate and eliminate viruses from pharmaceutical products, various methods are employed alone or in combination. Chromatographic methods, pH shift, extraction and fractionation using various organic solvents, salt precipitation, heat treatment, and filtration techniques are employed in case of structurally simple and stable products [Rabenau & Doerr (1990), "Die Infektionssicherheit biotechnologischer Pharmazeutika aus virologischer Sicht", p. 58 GIT VERLAG GmbH, Darmstadt]. Where sensitive or complex biological materials are involved, substances having an antiviral effect are frequently used. *Inter alia*, the following methods are employed:

- the combined use of solvents (e.g., extraction with ether) and synthetic detergents (e.g., Triton X-100) [Horowitz et al. (1985), *Transfusion* 25, 516-522];
- the use of β -propiolactone in combination with UV light as well as methylene blue in combination with photoactivation [W. Stephan (1989) pp. 122-127, in J.-J. Morge thaler (Ed.); *Virus Inactivation in Plasma Products* Curr. Stud. Hematol. Blood Transfus. No. 56, Karger Basel];
- pasteurization of liquid material [T. Nowak (1992), *Biologicals* 20, 83-85];

- heating of lyophilized material [D. Piszkievicz et al. (1989), pp. 44-54, in J.-J. Morgenthaler (Ed.), Virus Inactivation in Plasma Products., Curr. Stud. Hematol Blood Transfus. No. 56, Karger, Basel];
- irradiation with gamma rays (e.g., cobalt-60) [B. Horowitz et al. (1988), Transfusion 25, 523-527].

The literature describes a number of virus inactivation methods for blood products, particularly human blood plasma. Thus, in US 4,591,505, A.M. Prince discloses an inactivation method for hepatitis B virus wherein the blood products are added with alcohol and either a non-ionic detergent or an ether or a mixture of both as virus-inactivating agent. Polyoxyethylene derivatives or sulfobetaine are used as non-ionic detergents.

In US 4,841,023 and in Vox-Sang. 54, 14-20 (1988) S. Karger AG, Basel, B. Horowitz describes the inactivation of lipid-containing viruses in blood products by fatty acids, and in US 4,613,501 by C₁-C₄ alkyl oleic acid.

In EP 0,050,061 E. Shanbrom discloses a method of reducing undesirable effects such as pyrogenicity, hepatitis infectiousness, and aggregation in biological and pharmaceutical products, particularly blood products as well using a treatment with non-denaturing amphiphilics such as non-ionic surfactants (e.g., Tween 80).

The inactivation and elimination of viruses from cell cultures is effected using antiviral substances which normally inhibit virus replication.

None of the inactivation methods used up to now can safely inactivate or eliminate all viruses which may occur in biological material. Methods such as pasteurization and heat treatment normally require the use of stabilizers, and in addition, there is the problem of protein denaturation.

To date, the use of solvents and synthetic surfactants considered as suitable for inactivating lipid-enveloped viruses could not be assessed as entirely safe due to deviating results in inactivation kinetics or lacking systematic investigations as a result of high toxicity of the substances in cell cultures. Owing to their structure or stability, a variety of biotechnological products cannot be subjected to expensive purification or inactivation using product-damaging or cytotoxic antiviral substances such as solvents.

It was therefore the object of the invention to provide a mild method of inactivating lipid-enveloped viruses in biological or biotechnological products and cell cultures, which method enables to render these products or cell cultures free of viruses in an exceedingly rapid and effective fashion, with no denaturing of products or impairing the cell cultures in their productivity. Also, said method should allow the treatment of heat-labile products and avoid substances having *in vivo* toxicity.

The object of the invention is accomplished by using cyclic peptides containing β -hydroxyfatty acids and β -aminofatty acids (lipopeptides). These lipopeptides were found to have a surprisingly high inactivation potential for lipid-enveloped viruses, and thus, they are excellent for use in accomplishing the object of the invention. Part of these lipopeptides were found to be substantially more effective compared to synthetic surfactants used in virus inactivation up to now. In addition, they readily undergo biological degradation and have a substantially lower *in vivo* toxicity than synthetic surfactants. Compared to conventional antiviral substances, the lipopeptides used according to the invention have the advantage of thermal stability and good water-solubility.

From the literature, two [Ile⁷] and [Leu⁷] surfactins which belong to the lipopeptides, are known to exhibit moderate anti-HIV-1 activity (H. Itokawa et al., Chem. Pharm. Bull. 42, 604-607 (1994)). In Journal of Antibiotics, Japan XLIII 267-280 (1989), N. Naruse et al. describe pumilacidins as antivirally effective against herpes simplex virus (HSV-1). Neither of these papers indicates the considerable inactivation potential of these substances allowing extensive inactivation of lipid-enveloped viruses at low concentrations within an exceedingly short time.

Thus, the inactivation method according to the invention is characterized in that the biological or biotechnological products are added with a lipopeptide or a salt or ester thereof, or a mixture of lipopeptides or salts or esters thereof at an overall concentration of 1-100 μ M preferably 1-80 μ M, and that the inactivation is performed at room temperature within from 30 min to 2 hours at maximum, with about 99% of the viruses already being inactivated after 30 min. As a result of the exceedingly low *in vivo* toxicity of the lipopeptides used according to the invention, these inactivating substances may also be allowed to remain in the pharmaceutical products at the above-mentioned concentrations. Following inactivation, the lipopeptides employed may also be removed from the product by reversed phase HPLC on a C₁₈ column, or by adsorption chromatography on a silica gel column.

As the lipopeptides employed according to the invention are thermally stable, the inactivation process may also be performed at elevated temperatures, preferably 30-60°C, depending on the thermal stability of the product to be treated. The inactivation efficiency was found to have a linear temperature dependence. Thus, a temperature increase of about 10°C already results in an increase of the inactivation rate by a factor of about 2.4, so that virus inactivation is possible even within 5-30 min at 30-60°C.

the above-mentioned concentrations. In general, the viruses may also be inactivated at temperatures as low as 0°C. Depending on the particular species, however, this may take longer than 2 hours.

According to the invention, the virus inactivation in cell cultures is characterized in that the serum-free culture medium is added with a lipopeptide or a salt or ester thereof, or a mixture of lipopeptides or salts or esters thereof at an overall concentration of 1-65 μM , preferably 1-50 μM . When using a culture medium containing serum up to 5 vol.-%, e.g., FCS, the lipopeptide concentration required for complete inactivation is 10-100 μM , preferably 30-90 μM .

The inactivation process of the invention may be carried out within a broad pH range of 4-9, preferably 5.5-8.


Naturally occurring, chemically synthesized cyclic lipopeptides, as well as those produced and modified by genetic engineering may be used in the inactivation process of the invention.

The cyclic lipopeptides used according to the invention can readily be prepared according to previously described methods well-known to those skilled in the art. The *Bacillus subtilis* microorganism, among others, forms numerous lipopeptides *in vivo* which undergo secretion into the surrounding medium at high concentrations, from which they may be isolated.

Predominantly, viruses which can be inactivated by means of the method of the invention are herpes viruses, preferably HSV-1, HSV-2, BHV-1, SHV-1, immunodeficiency viruses, preferably HIV-1, HIV-2, SIV_{agm}, the vesicular stomatitis virus (VSV), and the Semliki-Forest virus (SFV).

According to the invention, however, other lipid-envelope viruses may also be inactivated effectively.

According to the invention, lipopeptapeptides of general formula I,



also referred to as surfactins, the salts, esters or mixtures thereof are preferably used in the inactivation, in which formula I X and Y represent the amino acids Leu, Ile or Val, Z represents the amino acids Val or Ala, and C₁₀₋₁₂ represents a linear or branched, saturated alkyl chain. According to the invention, the surfactins of general formula I, with X being Val or Ile, and the esters thereof are new compounds which are also subject of the present invention.

For example, the surfactin mixture produced by the strain *Bacillus subtilis* ATCC 21332 and the more productive strain *Bacillus subtilis* OKB 105 was found to be highly suitable in the virus inactivation according to the invention. The surfactin from these *Bacillus subtilis* strains is a mixture of isoforms, i.e., compounds of general formula I differing in the chain length of the fatty acid, the branching of the fatty acid, and the amino acids X, and Z, as illustrated above.

Individual compounds of general formula I, e.g. surfactin isoforms having a fatty acid residue of C₁₄ alkyl or C₁₅ alkyl (i.e., C₁₁ or C₁₂ alkyl in general formula I), which, for example, may be isolated from the surfactin mixture,

ture obtained by fermentation of the above-mentioned strains or synthesized by chemical means, likewise exhibiting a high inactivation potential. Thus, it has been determined that, e.g., surfactins of general formula I having C₁₅ alkyl as fatty acid residue inactivate vesicular stomatitis virus (VSV) even more rapidly compared to the surfactin mixture. Surfactins having C₁₄ alkyl as fatty acid residue were found to be effective compounds in the inactivation of porcine herpes virus (SHV-1).

Pumilacidins of general formula I in the form of individual components or mixtures, such as described in Journal of Antibiotics, Japan XLIII 267-280 (1989), pp 267-280, for example, as well as the salts or esters thereof may also be used according to the invention.

In one specific embodiment, compounds of general formula I wherein the amino acids Glu and/or Asp are esterified are employed in the process of the invention. The monoesters of the compounds of general formula I wherein just one of the above-mentioned amino acids is esterified, exhibit quite specific effects. Thus, the C₁₅ alkyl monoester of general formula I, for example, was found to inactivate the porcine herpes virus within minutes at a concentration of 40 μ M by a factor of $>10^4$. The C₁₅ alkyl monoesters of general formula I were also capable of inactivating the Semliki-Forest virus (SFV) within 20 minutes at a concentration of 40 μ M by a factor of $>10^4$. The inactivation of SFV using C₁₄ or C₁₅ alkyl monoesters is exemplified in Table 1 below:

Table 1: Inactivation of SFV

Lipopeptide	Incubation period (min)					
	0	1	5	10	15	20
	Titer (TCID ₅₀ /ml)					
Monoester C ₁₄	2.4×10 ⁴	1.7×10 ³	98.0	30.0	30.0	30.0
Monoester C ₁₅	2.5×10 ⁵	173.0	99.0	25.0	10.0	6.5

In the meaning of the invention, biological products represent products isolated from mammals, such as blood products, products isolated from blood, such as vaccines and plasma derivatives. Biotechnological pharmaceutical products are understood to be active substances produced by biotechnological means, such as human protein (hGH, TNF, t-PA, EPO), or coagulation factors (e.g., factor VIII); however, the invention is not limited to the above mentioned products from cell cultures.

With reference to the embodiments, the invention will be illustrated in more detail below.

Example 1

Preparation of surfactins of general formula I

The surfactin mixture used according to the invention, which contains the compounds of general formula I, prepared by cultivating *Bacillus subtilis* strains, particularly *Bacillus subtilis* ATCC 21332 or *Bacillus subtilis* 0105, and purified as described in Biochemical and Biophysical Research Communications, Vol. 177, No. 3 (1991), pp. 998-1005.

Example 2:

Isolation of the isoforms from the surfactin mixture prepared according to Example 1

The individual compounds of general formula I were isolated by preparative RP HPLC on EnCa Pharm 100 RP 18-T (5 μ m, 250 \times 16 mm) using an LKB HPLC system. The surfactin isoforms were eluted using acetonitrile gradients. Solvent A contained 40% acetonitrile and 60% 10 mM NH₄OAc (v/v), pH 6.9. Solvent B was 100% acetonitrile. Following lyophilization, the isoforms were obtained as a white powder and determined using NMR spectroscopy and MS spectrometry. The isolated compounds are shown in Table 2.

Table 2: Isolated isoforms

(In the following Table, the amino acid (AA) at position is valine, and AA2 is leucine, unless otherwise stated)

No. of fraction	Amino acids	Molecular mass in daltons	Fatty acid chain length
1	[Leu7]-	1008	C ₁₃
2	[Val7]-	994	C ₁₃
3	[Ile2, Val7]-	994	C ₁₃
4	[Leu7]-	1022	C ₁₄
	[Ile7]-	1008	C ₁₃
5	[Val7]-	1008	C ₁₄
6	[Ile2, Val7]-	1008	C ₁₄
7	[Leu7]-	1036	C ₁₅
8	[Ile7]-	1022	C ₁₄
9	[Val7]-	1022	C ₁₅
10	[Ile2, Val7]-	1022	C ₁₅
11	[Ile7]-	1036	C ₁₅
12	[Ile2, Ile7]-	1036	C ₁₅

The fractions 3, 6, 10, and 12 are new compound [Ile2, Val7]-surfactin and [Ile2, Ile7]-surfactin, which have not been described up to now. The ¹H-NMR data of the compounds in fractions 10 and 12 at 30°C in pyridine-d₅ are illustrated below:

Table 3:

Amino acid	Chemical shift					
	NH	C _α H	C _β H	C _γ H	C _δ H	
[Ile2, Val7]surfactin (fraction 10)						
	ppm					
L-Glu(1)	8.84	5.16	2.68,	2.51	2.88	-
L-Ile(2)	9.13	4.71	2.23	1.70,	1.39	1.18
D-Leu(3)	9.23	5.04	2.08,	1.87	1.87	0.93. 0.90
L-Val(4)	8.80	4.86	2.61	1.18		-
L-Asp(5)	9.25	5.60	3.50,	3.35	-	-
D-Leu(6)	8.72	5.20	1.96	1.96		0.90
L-Val(7)	8.88	4.92	2.50	1.12		-
Fatty acid	³ H 5.50	² H 2.98,	2.78	⁴ H 2.05,	1.90	¹ H 1.41, 1.25

Amino acid	Chemical shift					
	NH	C _α H	C _β H	C _γ H	C _δ H	
[Ile2, Ile7]surfactin (fraction 12)						
	ppm					
L-Glu(1)	8.80	5.17	2.67,	2.57	2.91	-
L-Ile(2)	9.10	4.72	2.24	1.70,	1.42	1.18
D-Leu(3)	9.25	5.04	2.07,	1.86	1.86	0.93. 0.90
L-Val(4)	8.80	4.86	2.63	1.19		-
L-Asp(5)	9.25	5.63	3.51,	3.38	-	-
D-Leu(6)	8.75	5.20	1.97	1.97		0.92
L-Ile(7)	8.84	4.96	2.22	1.70,	1.41	1.12
Fatty acid	³ H 5.50	² H 3.00,	2.79	⁴ H 2.06,	1.92	ⁿ H 1.43, 1.27

Example 3:

Preparation of monomethyl esters of the compounds of general formula I

An esterification of the surfactin mixture obtained in Example 1 was carried out using methanol/HCl, and the individual monomethyl esters were isolated. To prepare the monomethyl esters, 100 mg of surfactin mixture was incubated with 50 ml of methanol and 5 ml of HCl (pH 0.3) for 24 hours. The mixture was stirred at room temperature, and the solvent was removed under a vacuum. The surfactin/surfact

monomethyl ester/surfactin dimethyl ester ratio obtained was about 0.1:2:1. The monomethyl esters were isolated by means of preparative RP HPLC using the same column as described in Example 2. The acetonitrile gradient in this case was between 35 and 50% B. Table 4 illustrates the isolated surfactin monomethyl esters.

Table 4:

(In the following Table, the amino acid (AA) at position is valine, and AA2 is leucine, unless otherwise stated)

14	[Val7]-	1008	C ₁₃
15	[Leu7]-	1022	C ₁₃
	[Val7]-	1008	C ₁₃
16	[Leu7]-	1022	C ₁₃
	[Ile2, Val7]-	1008	C ₁₃
18	[Ile7]-	1022	C ₁₃
	[Val2, Val7]-	1008	C ₁₄
19	[]Ile7-	1022	C ₁₃
20	[Val7]-	1022	C ₁₄
21	[Leu7]-	1036	C ₁₄
22	[Val7]-	1022	C ₁₄
	[Ile2, Val7]-	1022	C ₁₄
23	[Leu7]-	1036	C ₁₄
24	[Ile7]-	1036	C ₁₄
25	[Val7]-	1036	C ₁₅
	[Ile7]-	1036	C ₁₄
26	[Leu7]-	1050	C ₁₅
	[Val7]-	1036	C ₁₅
27	[Leu7]-	1050	C ₁₅
	[Ile2, Val7]-	1036	C ₁₅
28	[Ile7]-	1050	C ₁₅
29	[Ile7]-	1050	C ₁₅
30	[Ile2, Ile7]-	1050	C ₁₅

Example 4:

Preparation of dimethyl esters of the compounds of general formula I

The esterification of 100 mg of the surfactin mixture from Example 1 was performed within 48 hours using 5 ml of 37% HCl and 50 ml of methanol. The diesters were the major products, and they were isolated as described in Example 3. Table 5 illustrates the isolated surfactin dimethyl esters.

Table 5

34	[Val7]-	1022	C ₁₃
35	[Leu7]-	1036	C ₁₃
36	[Ile7]-	1036	C ₁₃
37	[Val2, Val7]-	1022	C ₁₄
38	[Val7]-	1036	C ₁₄
39	[Leu7]-	1050	C ₁₄
40	[Ile7]-	1050	C ₁₄
	[Ile2, Val7]-	1036	C ₁₄
41	[Val7]-	1050	C ₁₅
42	[Leu7]-	1064	C ₁₅
43	[Ile7]-	1064	C ₁₅
	[Ile2, Val7]-	1050	C ₁₅
44	[Ile2, Ile7]-	1064	C ₁₅

The ¹H-NMR data of the diester of fraction 37 will be exemplified below, because this ester and the surfact

isoform which this ester is based upon is a new compound having the amino acid valine at position 2.

Table 6

Amino acid	Chemical shift					
	NH	C α H	C β H	C γ H	C δ H	
[Val2, Val7]surfactin dimethyl ester (fraction 37)						
	ppm					
L-Glu(1)	8.82	5.01	2.51,	2.39	2.71	-
L-Val(2)	9.05	4.63	2.43	1.20,	-	-
D-Leu(3)	9.20	5.03	2.06,	1.89	1.89	0.98, 0.91
L-Val(4)	8.75	4.79	2.51	1.14	-	-
L-Asp(5)	9.16	5.45	3.40,	3.17	-	-
D-Leu(6)	8.52	5.14	1.97	1.97	0.98,	0.91
L-Val(7)	9.03	4.91	2.45	1.13,	-	-
Fatty acid	^3H 5.50	^2H 2.93,	2.73	^4H 1.99,	1.85	^2H 1.38, 1.24

Example 5:

Determination of antiviral activity

To determine the antiviral activity of cyclic lipopeptides, herpes viruses were treated with the surfactin mixture from *Bacillus subtilis* (invariably referred to as surfactin hereinafter), and the number of infectious viruses

particles was determined as a function of time by seeding onto fresh host cells (final stage titration).

1. Herpes simplex virus type 1 (HSV-1) was taken up in 50 ml of Dulbecco's modified Eagle medium (ICN) including 5% (v/v) fetal calf serum (GIBCO) inactivated over 30 min at 56°C, and 80 µM of surfactin, sterile-filtered over a Nalgene syringe prefilter having a pore size of 0.1 µm. The initial titer was 5×10^5 ID₅₀/ml. By adding 1N HCl, the pH value of the inactivation batch was 7.0 constantly throughout the experiment, and the temperature was 22°C.
2. Aliquots were taken from the permanently stirred inactivation batch at intervals of 5, 10, 15, 30, 45, 60, 90, 120, and 180 minutes. Following a predilution of 1:10, these aliquots were used to produce a dilution series to the base 3. These dilutions were transferred to a 96-well flat-bottom microtiter plate (Nunc) into parallel rows, each having 100 µl of each dilution stage. Each of the 96 wells of the microtiter plate had previously been charged with 100 µl of a Vero cell suspension at a cell density of 1.5×10^5 cells/ml.
3. The plates were incubated for 6 days at 37°C at 5 vol.-% CO₂. The cells in the control batches with virus dilution had grown to high densities. The cell cultures of the microtiter plate were examined using a light microscope. All those cultures indicating a cytopathogenic effect were rated as infected.
4. The titers were calculated as 50% infectious dose (ID₅₀) according to the method of Spearman and Kärk [in: Biometrie. Grundzüge biologisch-medizinischer Statistik (1974), Ed.: L. Cavalli-Sforza, Gustav Fischer Verlag, Stuttgart, pp. 171-173] and correlated to 1 of inactivation batch.

Within a period of 15 minutes, the initial titer dropped from 5.1×10^5 ID₅₀ to a residual infectiousness of 2 ID₅₀. Following an incubation period of 30 minutes, the titer of infectious HSV-1 was 7 ID₅₀. After 60 minutes no infectious particles could be found anymore. Surfactin has a strong virucidal effect on herpes simplex virus, enabling an inactivation of 5log₁₀ HSV-1 particles in serum-containing culture medium within less than 60 minutes. Thus compared to inactivation methods used so far, the number of enveloped infectious virus particles had decreased at a substantially higher rate when using surfactin.

Example 6:

Determination of the activity spectrum

To determine the antiviral activity spectrum of cyclic lipopeptides, viruses considered particularly resistant to physical and chemical methods of inactivation among others, were treated with surfactin, and the remaining infectiousness of the virus particles was determined as a function of time.

1. The membrane-enveloped viruses listed in Table 1 were taken up in 50 ml of Dulbecco's modified Eagle medium (DMEM) including 5% (v/v) fetal calf serum (FCS) freshly inactivated over 30 min at 56°C, and 80 µM surfactin sterile-filtered over a Nalgene syringe prefilter having a pore size of 0.1 µm. The initial titers employed are illustrated in Table 1. By adding 1N HCl, the pH value of the inactivation batch was kept constantly throughout the experiment, and the temperature was 22°C.

Table 1: Virus/cell systems used in the inactivation experiments

Virus	Initial titer [ID ₅₀ /ml]	Host cell line	Model virus for
Porcine herpes virus (SHV-1)	1.6×10^5	Mink lung cells	human herpes viruses
Bovine herpes virus (BHV-1)	4.3×10^5	Bovine kidney cells	human herpes viruses
Herpes simplex virus type 2 (HSV-2)	4.2×10^4	Simian kidney cells	
Simian immuno- deficiency virus (siv _{agm})	1.6×10^5	Human helper T cells	human immuno- deficiency virus
Vesicular stomatitis virus (VSV)	9.5×10^6	Baby hamster fibroblasts	frequently used model virus
Semliki-Forest virus (SFV)	7.0×10^7	Baby hamster fibroblasts	western/eastern horse encephali

2. Aliquots were taken from the permanently stirred inactivation batch at intervals of 5, 10, 15, 30, 45, 60, 90, 120, and 180 minutes. Following a predilution of 1:10, these aliquots were used to produce a dilution series to the base 3. These dilutions were transferred to a 96-well flat-bottom microtiter plate (Nunc) into parallel rows, each having 100 μ l of each dilution stage. According to the proliferation rate of the host cell, each of the 96 wells of the microtiter plate had previously been charged with 100 μ l of the corresponding host cell suspension (Table 1) at cell densities about 1.5×10^5 - 5×10^4 cells/ml.

3. Depending on the particular cell line, the plates were incubated for 6 - 18 days at 37°C and 5 vol.-% CO₂.

The cells in the control batches with no virus dilution had grown to high densities. The cell cultures of the microtiter plate were examined using a light microscope. All those cultures indicating a cytopathogenic effect were rated as infected. As a result of insufficient light-microscopic evaluability, the cytopathogenic effect of SIV_{agm} on the MOLT 4/8 human helper T cell line was determined according to the description of the cell proliferation-dependent test according to Mosman [J. Immunol. Meth. 65, 55-63, 1983] using the MTT dye.

4. The titers were calculated according to the description in Example 1, section 5.

All of the above-listed enveloped viruses could be inactivated by using surfactin in a serum-containing medium. After 120 minutes, less than 0.02% of the employed SHV-1, BHV-1, and HSV-2 infectiousness could be detected. With the viruses VSV and SIV_{agm}, such a ratio of residual infectiousness was reached after an incubation period of only 60 minutes. The surfactin lipopeptide acts directly on a variety of lipid-enveloped viruses at a high inactivation rate.

Example 7:

Effect of lipopeptide concentration

The effect of the concentration of cyclic lipopeptide on the inactivation efficiency may be quantified by determining the inactivation rate (decrease of virus infectiousness per inactivation time).

1. Porcine herpes virus (SHV-1) was taken up in 25% of Dulbecco's modified Eagle medium (DMEM) including

(v/v) fetal calf serum (GIBCO) inactivated over 30 min at 56°C, and surfactin concentrations of 0, 10, 20, 30, 40, 50, 60, 70, 75, 80, 90, and 100 µM, respectively. To this end, the surfactin was dissolved in culture medium and sterile-filtered over a syringe prefilter (Nalgene, pore size 0.1 µm). The initial titer was 2×10^4 ID₅₀/ml. The temperature in the permanently stirred inactivation batch was 22°C, and the pH value was 7.8.

2. Following addition of surfactin, aliquots were taken from the inactivation batch at intervals of 2, 5, 10, 15, and 20 minutes and immediately subjected to 1:10 predilution in medium.
3. Using these predilutions, a dilution series to titer base 3 was produced. The dilutions were transferred to a 96-well flat-bottom microtiter plate (Nunc) into parallel rows, each having 100 µl of each dilution stage. Each of the 96 wells of the microtiter plate had previously been charged with 100 µl of a mink lung cell suspension at a cell density of about 1.0×10^5 cells/ml.
4. The incubation of the cell cultures in the microtiter plates, the evaluation of these microtiter plates, and the calculation of the titer of remaining infectious virus at the respective times of withdrawal were carried out according to the description in Example 1, sections 4 and 5.

The inactivation rate increases exponentially with the lipopeptide concentration. Within a lipopeptide concentration range of from 10 to 80 µM surfactin, the inactivation rate increased from 0.19 to 0.6 log₁₀ ID₅₀/10 min. At surfactin concentration of 100 µM, the employed infectious SHV-1 particles were inactivated at a rate of 1.4 log ID₅₀/10 min. The surfactin lipopeptide permits inactivation

of lipid-enveloped viruses within a broad concentration range. The lipopeptide concentration may be selected according to product properties and process profile.

Example 8:

Virus inactivation at various reaction temperatures

The effect of temperature on the virus inactivation during the inactivation reaction may be quantified by determining the inactivation rate (decrease of virus infectiousness per inactivation time).

1. Porcine herpes virus (SHV-1) was taken up in 25 ml of Dulbecco's modified Eagle medium (ICN) including (v/v) fetal calf serum (GIBCO) inactivated over 30 min at 56°C and surfactin at a concentration of 80 µM. The surfactin was dissolved in culture medium and sterile filtered over a syringe prefilter (Nalgene, pore size 0.1 µm). The initial titer was 1×10^5 ID₅₀/ml. By adding 1N HCl, the pH value of the inactivation batch was 7 constantly throughout the experiment. The respective inactivation batches were adjusted to 5, 10, 15, 20, 25, and 30°C with an accuracy of $\pm 0,01^\circ\text{C}$ in a water bath [Grant, model W14-ZD/CZ1] and stirred permanently.
2. Following surfactin addition, aliquots were sampled at intervals of 2, 5, 10, 15, and 20 minutes and immediately subjected to a 1:10 predilution in medium.
3. Using these predilutions, a dilution series to titer base 3 was produced. The dilutions were transferred into a 96-well flat-bottom microtiter plate (Nunc) into parallel rows, each having 100 µl of each dilution stage. Each of the 96 wells of the microtiter plate had

previously been charged with 100 μ l of a mink lung cell suspension at a cell density of about 1.0×10^5 cells/ml.

4. The incubation of the cell cultures in the microtiter plates, the evaluation of these microtiter plates, and the calculation of the titer of remaining infectious virus at the respective times of withdrawal were carried out according to the description in Example 1, sections 4 and 5.

Within the tested temperature range of from 5 to 30°C, there was significant inactivation of SHV-1 in the serum-containing culture medium. The inactivation rate increased linearly from 0.05 at 5°C, via 0.25 at 20°C, and to 0.45 log₁₀ ID₅₀/min at 30°C. The surfactin lipopeptide permits treatment of heat-labile products in order to inactivate lipid-enveloped viruses, as well as time-saving, rapid inactivation at high temperatures.

Example 9:

Determination of cytotoxicity of surfactin on adherent cells

The cytotoxic effect of cyclic lipopeptides on adherent cells in a culture was determined according to modification of the crystal violet test by D.A. Flick and G.E. Gifford [J. Immunol. Meth. 68, 167-175, 1984].

1. Cells of the lines ML (mink lung cells), CV1 (guinea pig kidney cells), Hep2 (human epithelial cells), CRFK (cat kidney cells), and BHK21 (hamster kidney cells) freshly treated with trypsin were taken up in Dulbecco's modified Eagle medium (DMEM) including (v/v) fetal calf serum (FCS) freshly inactivated or

30 min at 56°C, and 100 µl of cell suspension (about $1-2 \times 10^5$ cells/ml) was pipetted into each well of a 96 well flat-bottom culture plate (Nunc). The culture was incubated for 3 hours at 37°C in the presence of 5 vol.-% CO₂.

2. Surfactin dissolved in culture medium was sterile filtered (Nalgene syringe prefilter, pore size 0.1 µm) and diluted to various concentrations using fresh culture medium. 50 µl of the nutrient medium including various concentrations of surfactin was added to the grown cells. The culture plate was incubated for another 2 days at 37°C and in the presence of 5 vol.-% CO₂.

3. After 3 days, the cells of the lines ML, Hep₂, and BHK21, and after 8 days, the cells of the lines CV1 and CRFK had grown to high cell densities, forming homogeneous cell lawns. The medium supernatant was discarded and 50 µl of crystal violet solution was pipetted into each batch. The crystal violet solution was composed of 3.75 g of crystal violet, 1.75 g of NaCl, 161.5 ml of absolute ethanol, 43.2 ml of 37% formaldehyde (all chemicals supplied by Merck) and 500 ml of deionized and distilled water. After 20 min, the crystal violet solution was thoroughly washed out of the cavities using deionized water, and the microtiter plate was air dried.

4. The remaining cell-bound dye was dissolved by adding 100 µl of a solution of 50% absolute ethanol, 0.1% of glacial acetic acid, 49.9% of deionized and distilled water per cavity and dispersed homogeneously with intense agitation for 5 minutes. The photometric determination of the color intensity which is in linear relationship to the cell density, was effected at 550 nm (EAR 400 AT, SLT-Labinstruments). The concentration r

sulting in a 50% reduction of the cell number was determined.

A cytotoxic effect of 50% at a medium concentration of 48 μM for the Hep₂, 37 μM for the BHK21, 45 μM for the CRFK, and 43 μM for the ML cells was determined with surfactin. The CRFK and Hep₂ cells did not exhibit any change in cellular growth at surfactin concentrations of up to 30 μM . With ML and BHK21 cells, a reduction in growth of about 15% was observed at such a surfactin concentration. In long-term examinations, a surfactin concentration of 40 μM as used in Example 1 resulted in a cell density reduction to 15% for the CRFK and Hep₂ cells, to 45% for the ML cells, and to 57% for the BHK21 cells compared to non-treated control batches. None of the tested cultures tolerated surfactin concentrations higher than 65 μM . All of the tested cell cultures tolerated the presence of the surfactin lipopeptide over the short period of time required for the inactivation of lipid-enveloped viruses.

Example 10:

Biotechnological application

Inactivation of enveloped viruses in cell cultures

Using genetic engineering, any cell line will be capable of producing potentially valuable substances such as interferons, growth factors, etc.. Circumstantially such cell cultures may be contaminated by various virus species. Therefore, virus contaminations should be removed at such an early stage as the starting cell culture. The elimination of a herpes virus from a mink lung cell culture will now be described as an example. Porcine herpes virus type 1 (SHV-1) induces a distinct cytopathogenic effect, the absence thereof being a direct evidence for the success of inactivation.

1. In a Petri dish (\emptyset 10 cm, Nunc), about 1×10^4 ML cell (mink lung cells) freshly treated with trypsin were subjected to a passage using Dulbecco's modified Eagle medium (ICN) including 5% (v/v) fetal calf serum (GIBCO) inactivated over 30 min at 56°C . The cell culture medium was removed from the grown cells which were infected with about 100 TCID₅₀ of SHV-1. Following a one hour incubation, the inoculum was removed and the cell lawn was covered with a layer of 10 ml of Dulbecco's modified Eagle medium (ICN) including 5% (v/v) fetal calf serum (GIBCO) and 50 μM of surfactin. To this end the surfactin was dissolved in PBS at a concentration of 1 mM and autoclaved (23 min at 123°C).
2. The ML cell culture was incubated for 3 days at 37°C and 5 vol.-% CO_2 . The cells covered 30% of the Petri dish bottom, and their removal was possible using 0.25% trypsin, 2 μM EDTA. In a Petri dish (\emptyset 10 cm, Nunc) all the cells were subjected to a further passage with Dulbecco's modified Eagle medium (ICN) including 5% (v/v) fetal calf serum (GIBCO) inactivated over 30 min at 56°C , and 40 μM surfactin. The treatment was repeated twice.
3. Subsequent to ten passages with no surfactin, 1 ml of cell culture supernatant was placed on a fresh ML cell culture which, following 7 days of incubation, was then examined for a virus-related cytopathogenic effect (CPE) using a light microscope.

No cytopathogenic effect as an indication of virus growth could be observed in the ML cell cultures.

Example 11:

Product safety

Inactivation of SIV in an albumin solution

Serum contains a variety of economically and medically important components such as hormones, immunoglobulins, coagulation factors, enzymes, cholesterol, lipoproteins, albumins, etc.. A serum may be fractionated using organic solvents such as ethanol, ether, polyethylene glycol at low temperatures, and by precipitation using salt or a pH change, thus purifying the components. However, viruses occurring in blood, such as the HIV retrovirus may be present in the purified blood product as infectious particles. As an example of a virus inactivation to follow necessarily, bovine serum albumin (BSA) was treated with surfactin. To demonstrate the efficacy, albumin was added with a dose of simian immunodeficiency virus (SIV) not encountered under natural conditions, and the number of infectious virus particles was determined as a function of time by seeding onto fresh host cells (final stage titration).

1. Simian immunodeficiency virus (SIV) was taken up in 50 ml of PBS including 50 mg/ml BSA and 80 μ M surfactin (dissolved in PBS at a concentration of 1 mM and autoclaved). The initial titer was 1.6×10^5 TCID₅₀/ml. After adding 1N HCl, the pH value of the inactivation batch was 7.8 constantly throughout the experiment, and the temperature was 22°C.
2. Aliquots were taken from the permanently stirred inactivation batch at intervals of 5, 10, 15, 30, 45, 60, 90, 120, and 180 minutes. Following a predilution of 1:10, these aliquots were used to produce a dilution series to the base 3. These dilutions were transferred on a 96-well flat-bottom microtiter plate (Nunc) into parallel rows, each having 100 μ l of each dilution.

stage. Each of the 96 wells of the microtiter plate had previously been charged with 100 μ l of a Molt4, Klon cell suspension at a cell density of 5×10^4 cells/ml.

3. The plates were incubated for 14 days at 37°C and 5 vol.-% CO₂. The cells in the control batches with no virus dilution had grown to high densities. The cell cultures of the microtiter plate were examined using a light microscope. All those cultures indicating a cytopathogenic effect were rated as infected.
4. The titers were calculated as 50% infectious dose (TCID₅₀) according to the method of Spearman and Kärber [in: Biometrie. Grundzüge biologisch-medizinischer Statistik (1974), Ed.: L. Cavalli-Sforza, Gustav Fischer Verlag, Stuttgart, pp. 171-173] and correlated to 1 ml of inactivation batch.

Within a period of 15 minutes, the initial titer dropped from 1.6×10^5 TCID₅₀ to a residual infectiousness of 1.5×10^3 TCID₅₀. After an incubation period of 60 minutes the titer of infectious SIV was 7 TCID₅₀. After 120 minutes no infectious particles could be found anymore.

Example 12:

Product safety

Combined use of surfactin and moist heat for inactivation of SIV in an albumin solution

Once isolated and purified, products obtained from blood and biotechnology are frequently subjected to a heat treatment (pasteurization). Such a heat treatment may be combined with an SD process. Owing to its thermal stability, surfactin may also be used in combination with a heat inactivation procedure. The example describes the inactivation

tion of simian immunodeficiency virus (SIV) in serum albumin in order to demonstrate the synergistic effect of heat and surfactin on the virus inactivation.

1. Simian immunodeficiency virus (SIV) was taken up in 50 ml of PBS including 50 mg/ml BSA and 80 μ g surfactin (dissolved in PBS at a concentration of 1 mg/ml and autoclaved). The initial titer was 1.6×10^6 TCID₅₀/ml. By adding 1N HCl, the pH value of the inactivation batch was 7.8 constantly throughout the experiment. Prior to adding the virus suspension, the batch had been preheated to 60°C on a water bath and held constant during the experiment.
2. Aliquots were taken from the permanently stirred inactivation batch at intervals of 2, 5, 10, 15, 30, 45, and 60 minutes. Following a predilution of 1:10, these aliquots were used to produce a dilution series to the base 3. These dilutions were transferred to 96-well flat-bottom microtiter plate (Nunc) into 8 parallel rows, each having 100 μ l of each dilution stage. Each of the 96 wells of the microtiter plate had previously been charged with 100 μ l of a Molt4, Klon 8 cell suspension at a cell density of 5×10^4 cells/ml.
3. The plates were incubated for 14 days at 37°C at 5 vol.-% CO₂. The cells in the control batches with virus dilution had grown to high densities. The cell cultures of the microtiter plate were examined using light microscope. All those cultures indicating a cytopathogenic effect were rated as infected.
4. The titers were calculated as 50% infectious dose (TCID₅₀) according to the method of Spearman and Kärber [in: Biometrie. Grundzüge biologisch-medizinischer Statistik (1974), Ed.: L. Cavalli-Sforza, Gustav Fischer Verlag, Stuttgart].

Verlag, Stuttgart, pp. 171-173] and correlated to 1 m of inactivation batch.

Within a period of 5 minutes, the initial tite dropped from 1.6×10^5 TCID₅₀ to a residual infectiousness of 9.3×10^2 TCID₅₀. After 20 minutes of incubation, no infectious particles could be found anymore. When using the combined heat/surfactin procedure, the infectiousness of introduced SIV was inactivated more rapidly by a factor of at least 10 compared to an equal surfactin concentration at room temperature or by heat treatment with no antiviral additives.

Example 13:

Maximum inactivation rates:


The maximum attainable inactivation rates were determined for three virus families. The inactivation conditions were: pH 7.8; 80 µM surfactin; aqueous medium including 5% fetal calf serum; stirring; 22°C.

Virus	Drop in infectiousness [\log_{10} TCID ₅₀ [#]]			
	after 5 min	after 30 min	after 60 min	after 120 min
Herpes viruses	2.30	4.90	5.40	-
Retroviruses	1.30	2.90	4.40	-
Rhabdoviruses	1.00	3.60	4.50	5.40

Dose infecting 50% of tissue culture

Claims:

1. A method of inactivating lipid-enveloped viruses in biological or biotechnological products or cell cultures, characterized in that the products or cell cultures are added with a cyclic lipopeptide salts or esters thereof, or mixtures of same as inactivating agent, and inactivation is performed at room temperature within from 30 minutes up to 2 hours maximum, wherein
 - a) the agent is added to said products at a concentration of 1-100 μ M when inactivating viruses in the products;
 - b) the agent is added to the serum-free culture medium at a concentration of 1-65 μ M, or to the serum-containing culture medium at a concentration of 10-100 μ M when inactivating viruses in cell cultures.
2. The method of claim 1, characterized in that the virus inactivation in biological or biotechnological products is performed at temperatures higher than room temperature, preferably 30-60°C, within a period 5-30 min.
3. The method according to claim 1 or 2, characterized in that naturally occurring, chemically synthesized lipopeptides, as well as those produced or modified by genetic engineering are used as cyclic lipopeptides.
4. The method according to any of claims 1-3 characterized in that lipopeptides of general formula I,




the salts, esters or mixtures thereof are used as lipopeptides, in which formula I X and Y independently represent the amino acids Leu, Ile or Val, Z represent the amino acids Val or Ala, and C₁₀₋₁₂ represents a linear or branched, saturated alkyl chain.

5. The method according to claim 4, characterized in that compounds of general formula I with C₁₁ alkyl or C₁₂ alkyl are used.
6. The method according to claim 4 or 5, characterized in that esters of the compounds of general formula I, preferably monoesters are employed.
7. The method according to any of claims 4-6 characterized in that compounds of general formula I are used, wherein X and Y represent Leu, and Z represents Val.
8. The method according to any of claims 4-6 characterized in that compounds of general formula I are used, wherein X represents Ile or Val.
9. The method according to any of claims 1-8 characterized in that lipid-enveloped human and animal viruses are inactivated.

10. The method according to any of claims 1-8 characterized in that herpes viruses, preferably HSV-1 HSV-2, BHV-1, SHV-1, immunodeficiency viruses, preferably HIV-1, HIV-2, SIV_{agm}, the vesicular stomatitis virus (VSV), and the Semliki-Forest virus (SFV) are inactivated.

11. New lipopeptides of general formula I



and the salts and esters thereof, in which formula I and Y independently represent Val or Ile, and Z represents Val.

12. Use of the lipopeptides according to claim 1 for inactivating lipid-enveloped viruses in biological or biotechnological products, or in cell cultures.

Abstract

The invention relates to an extraordinarily efficient method of inactivating lipid-enveloped viruses, such as herpes or retroviruses, in biological or biotechnological - particularly pharmaceutical - products, as well as in cell cultures by adding a cyclic lipopeptide or a mixture of lipopeptides or salts or esters thereof at specific concentrations. Lipopeptides were found to have a surprisingly high inactivation potential for lipid-enveloped viruses and in addition, they offer the advantage of an exceedingly low *in vivo* toxicity, so that the step of removing the inactivating agent from pharmaceutical products or cell culture can be omitted. The invention is also directed to new antiviral lipopeptides which belong to the surfactins.

BIRCH, STEWART, KOLASCH & BIRCH, LLP

P.O. Box 747 • Falls Church, Virginia 22040-0747

Telephone: (703) 205-8000 • Facsimile: (703) 205-8050

ATTORNEY DOC
2694-119P

PLEASE NOTE:
YOU MUST
COMPLETE THE
FOLLOWING:



COMBINED DECLARATION AND POWER OF ATTORNEY FOR PATENT AND DESIGN APPLICATIONS

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated next to my
verly believe that I am the original, first and sole inventor (if only one inventor is named below) or an original, first and joint
plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention

Insert Title: →

NEW ANTIVIRAL LIPOPEPTIDES, AND A METHOD OF INACTIVATING
LIPID-ENVELOPED VIRUSES USING LIPOPEPTIDES

Fill in Appropriate
Information —
For Use →
Without
Specification
Attached:

the specification of which is attached hereto. If not attached hereto,

the specification was filed on February 12, 1999
United States Application Number _____
and amended on _____ (if applicable); and
the specification was filed on August 11, 1997 as P
International Application Number PCT/EP97/04353; and
amended under PCT Article 19 on _____ (if applicat

I hereby state that I have reviewed and understand the contents of the above identified specification, including th
amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal
§1.56.

I do not know and do not believe the same was ever known or used in the United States of America before my or
thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than o
to this application, that the same was not in public use or on sale in the United States of America more than one year
application, that the invention has not been patented or made the subject of an inventor's certificate issued before the
application in any country foreign to the United States of America on an application filed by me or my legal representativ
more than twelve months (six months for designs) prior to this application, and that no application for patent or inventor's
this invention has been filed in any country foreign to the United States of America prior to this application by me or my legal re
or assigns, except as follows.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a)-(d) of any foreign application(s)
inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certific
filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

Insert Priority
Information: →
(if appropriate)

(Number)	(Country)	(Month / Day / Year Filed)	Prior
<u>196 33 684.8</u>	<u>Germany</u>	<u>August 12, 1996</u>	<input checked="" type="checkbox"/> Yes
_____	_____	_____	<input type="checkbox"/> Yes
_____	_____	_____	<input type="checkbox"/> Yes
_____	_____	_____	<input type="checkbox"/> Yes

Insert Provisional
Application(s): →
(if any)

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) liste

(Application Number)	(Filing Da
_____	_____
_____	_____

All Foreign Applications, if any, for any Patent or Inventor's Certificate Filed More than 12 Months (6 Months for Design
Filing Date of This Application:

Insert Requested
Information: →
(if appropriate)

Country	Application Number	Date of Filing (Month
_____	_____	_____
_____	_____	_____

Insert Prior U.S.
Application(s): →
(if any)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States and/or PCT application(s) liste
insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States and/or PCT
the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose infor
is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the
the prior application and the national or PCT international filing date of this application:

(Application Number)	(Filing Date)	(Status — patented, pending, ab
_____	_____	_____
_____	_____	_____

I hereby appoint the following attorneys to prosecute this application and/or an international application based on this and to transact all business in the Patent and Trademark Office connected therewith and in connection with the resulting patent instructions received from the entity who first sent the application papers to the attorneys identified below, unless the assignee provides said attorneys with a written notice to the contrary:

Raymond C. Stewart	(Reg. No. 21,066)	Terrell C. Birch	(Reg. No. 19,382)
Joseph A. Kolasch	(Reg. No. 22,463)	James M. Slaterry	(Reg. No. 28,380)
Bernard L. Sweeney	(Reg. No. 24,448)	Michael K. Mutter	(Reg. No. 29,680)
Charles Gorenstein	(Reg. No. 29,271)	Gerald M. Murphy, Jr.	(Reg. No. 28,977)
Leonard R. Svensson	(Reg. No. 30,330)	Terry L. Clark	(Reg. No. 32,644)
Andrew D. Meikle	(Reg. No. 32,868)	Marc S. Weiner	(Reg. No. 32,181)
Joe McKinney Muncy	(Reg. No. 32,334)	C. Joseph Faraci	(Reg. No. 32,350)
Donald J. Daley	(Reg. No. 34,313)	John W. Bailey	(Reg. No. 32,881)
John A. Castellano	(Reg. No. 35,094)		

Send Correspondence to: **BIRCH, STEWART, KOLASCH & BIRCH, LL**
P.O. Box 747 • Falls Church, Virginia 22040-0747
Telephone: (703) 205-8000 • Facsimile: (703) 205-8050

**PLEASE NOTE:
YOU MUST
COMPLETE
THE
FOLLOWING:**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information believed to be true; and further that these statements were made with the knowledge that willful false statements so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of First or
Sole Inventor
Insert Name of
Inventor →
Insert Date This
Document is Signed

Insert Residence →
Insert Citizenship

Insert Post Office →
Address

Full Name of Second
Inventor, if any
see above

Full Name of Third
Inventor, if any
see above

Full Name of Fourth
Inventor, if any
see above

Full Name of Fifth
Inventor, if any
see above

GIVEN NAME	FAMILY NAME	INVENTOR'S SIGNATURE	DATE
Dirk	VOLLENBROICH	<i>[Signature]</i>	18
Residence (City, State & Country)		CITIZENSHIP	
Berlin, Germany		German	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country)			
Allerstraße 6, 12049 Berlin, Germany <i>DOX</i>			
GIVEN NAME	FAMILY NAME	INVENTOR'S SIGNATURE	DATE
Joachim	VATER	<i>[Signature]</i>	16
Residence (City, State & Country)		CITIZENSHIP	
Berlin, Germany		German	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country)			
Nibelungenstraße 14c, 14109 Berlin, Germany <i>DEK</i>			
GIVEN NAME	FAMILY NAME	INVENTOR'S SIGNATURE	DATE
Georg	PAULI	<i>[Signature]</i>	18
Residence (City, State & Country)		CITIZENSHIP	
Berlin, Germany		German	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country)			
Lutzowstraße 51f, 10785 Berlin, Germany <i>DEK</i>			
GIVEN NAME	FAMILY NAME	INVENTOR'S SIGNATURE	DATE
Roza Maria	KAMP	<i>[Signature]</i>	1
Residence (City, State & Country)		CITIZENSHIP	
Berlin, Germany		German	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country)			
Knesebeckstraße 9a, 14167 Berlin, Germany <i>DOX</i>			
GIVEN NAME	FAMILY NAME	INVENTOR'S SIGNATURE	DATE
Residence (City, State & Country)		CITIZENSHIP	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country)			